News
Zoom out: The positive results sent Lilly's stock soaring 16% Thursday to $852. Bank of America's Anderson projected 2030 ...
Drugmaker Eli Lilly announced promising Phase 3 study results for its new GLP-1 pill.Orforglipron is a drug similar to ...
Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...
The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...
The first GLP-1 pill could be in medicine cabinets sooner than expected. Eli Lilly (LLY) announced Thursday that its daily ...
Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...
Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...
Shares in pharmaceuticals firm Eli Lilly (LLY) ballooned higher today after revealing its new needle-free weight loss drug had performed ...
Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...
The jab averse can now rejoice! Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, stab-free way to treat diabetes and obesity.
Eli Lilly (LLY) stock surges after releasing promising ... The pill would offer an alternative to popular weight loss injections like Ozempic. Our very own, Anjali Khemlani, joins us with the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results